lymphocytes from patients with colorectal cancer (Nakagomi et al, 1993; Matsuda et al, 1995; Mulder et al, 1997) , renal cell carcinoma (Finke et al, 1993; Kono et al, 1996b) , ovarian cancer (Lai et al, 1996) , and melanoma (Zea et al, 1995) . Moreover, inverse correlations between the level of CD3-ζ chain expression, the stage of colorectal carcinoma (Matsuda et al, 1995; Mulder et al, 1997) , and the survival rate among melanoma patients (Zea et al, 1995) , strongly suggest that such a reduction in CD3 ζ chain expression indeed leads to an impaired tumour-specific immunity. In line with this, the absence of ζ chains has been correlated to a reduced proliferative and cytokine production capacity of mature T-cells (Mizoguchi et al, 1992; Finke et al, 1993; Zea et al, 1995; Tartour et al, 1995; Lai et al, 1996) .
In patients with colorectal carcinoma the level of CD3-ζ expression on mucosal T-cells was found to be inversely related to their distance from the tumour site (Matsuda et al, 1995) . In addition, both in renal cell and in colorectal cancer patients, a higher expression of CD3-ζ was found on peripheral T-cells than on tumourinfiltrating T-cells (Finke et al, 1993; Nakagomi et al, 1993; Matsuda et al, 1995) . These results indicate that the observed loss of ζ chain expression may be caused by tumour-derived factors. We have previously studied local and systemic immune parameters in patients with malignant and premalignant lesions of the cervix uteri (Cromme et al, 1993 (Cromme et al, , 1995 de Gruijl et al, 1996a de Gruijl et al, , 1996b . The development of cervical cancer is strongly associated with the presence of oncogenic human papillomavirus (HPV) Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes types (IARC, 1995) . The failure of the host immune system to raise effective immune responses to HPV-derived antigens is believed to play an important role in cervical carcinogenesis. This is exemplified by increased prevalences of HPV-induced cervical lesions in patients with impaired cellular immune functions such as renal transplant recipients and AIDS patients (Frazer, 1996) . Recently, a reduced expression of CD3-ζ and CD16-ζ on peripheral blood lymphocytes (PBL) from women with premalignant and malignant cervical lesions was reported (Kono et al, 1996a) . This altered ζ chain expression was related to a reduced production of tumour necrosis factor (TNF) upon polyclonal activation of peripheral T-cells.
As ζ chain loss might represent a critical factor contributing to an impaired HPV-specific T-cell-mediated immune response, we decided to investigate the in situ ζ chain expression in primary and metastatic cervical carcinoma-infiltrating lymphocytes using immunohistochemical methods.
MATERIALS AND METHODS

Patients and specimens
Archives of the Pathology Departments of the Netherlands Cancer Institute, the Free University Hospital and the Academic Medical Center, Amsterdam, The Netherlands, were searched for primary squamous cell cervical carcinoma specimens stored after 1994. Whenever possible, frozen and fixed material from primary tumours and the corresponding tumour-positive or -negative pelvic lymph nodes were retrieved. Twenty-five different cases were identified. Paraffin-embedded tissue samples (n = 16) and frozen biopsies (n = 13) from in total 24 primary tumours were collected. For five primary tumours both frozen and paraffin material was available. Paraffin blocks of tumour-negative (n = 15) and of tumourpositive lymph nodes (n = 7) were retrieved. After histologic and clinical file review, all cases were classified as moderately (6/25) or poorly differentiated (19/25) squamous cell cervical carcinoma and staged IbÐIIa according to the International Federation of Gynaecology and Obstetrics (FIGO) staging system. Median patient age was 47.8 years (25Ð78). All patients had undergone radical hysterectomy with pelvic lymph node dissection as primary surgery. In addition, three biopsies from cervical intraepithelial neoplasia (CIN) patients (CIN III) and three cervical biopsies without epithelial abnormalities were collected. As positive controls, five hyperplastic tonsils were tested.
Monoclonal and polyclonal antibodies
The anti-TCR ζ monoclonal antibody TIA-2 (Coulter Clone, Almere, NL), recognizing a cytoplasmic epitope of the TCR-associated ζ chain was used to identify ζ chain-positive cells (dilution 1:25). To stain the CD3 complex, the mouse monoclonal antibody Leu4 (Becton Dickinson, San Jose, CA, USA, dilution 1:10), or rabbit polyclonal antibody A542 (DAKO, Glostrup, Denmark, dilution 1:2000), both recognizing the CD3-ε chain, were used.
Immunohistochemistry
Four 4-µm thick tissue sections were consecutively cut from each specimen. Paraffin sections were mounted on 3% aminopropyltriethoxysilane-coated (Sigma, Deisenhofen, Germany) slides, deparaffinized and rehydrated. After endogenous peroxidase quenching (0.3% hydrogen peroxide methanol for 30 min), antigens were ÔretrievedÕ either by boiling sections in sodium citrate buffered solution (0.1 mM, pH 6.0) in a 750 kW microwave oven at maximum power for 10 min (TIA-2) or by preincubating them with 0.1% pronase E (Sigma, Deisenhofen, Germany) for 30 min at 37°C (CD3-ε). No antigen retrieval was used for TIA-2 or CD3-ε staining on frozen sections. Primary antibodies and isotypematched negative control antibodies at the appropriate dilutions were incubated at room temperature (RT) for 1 h, except for the rabbit polyclonal antibody A542 (O/N, 37°C). A biotinylated secondary antibody to mouse or rabbit immunoglobulins (1:25, 30 min, RT, Dakopatts, Glostrup, Denmark) was followed by a mouse monoclonal antibody directed against biotin (1:200, 30 min, RT, Southern Biotechnology Associates, IN, USA). Complexed streptavidin-biotinylated horseradish peroxidase or alkaline phosphatase was added (1:200 for 1 h, Dakopatts, Glostrup, Denmark) and staining was visualized with diaminobenzidine or new fuchsine on paraffin and frozen sections, respectively. In each experiment, hyperplastic tonsils were included as positive controls.
Scoring of CD3-ε+ and CD3-ζ+ cells
Slides were examined and quantitatively scored by two independent observers: a total of 100 tumour-infiltrating CD3-ε+ cells were counted in randomly selected high power fields (400 ×) of tumour areas and CD3-ζ+ cells were similarly scored in the same areas on consecutive slides. In lymph nodes, all CD3-ε+ cells were counted present in five HPF of interfollicular spaces or subcapsular sinuses. In the case of tumour-positive lymph nodes, HPF were selected in the proximity of metastasizing tumour nests. For each specimen, the CD3-ζ/ε ratio was calculated and samples were scored as follows: Ð, ζ/ε = 0; +, 0 < ζ/ε < 0.33; ++, 0.33 < ζ/ε < 0.66; +++, 0.66 < ζ/ε < 1.0. ζ Chain expression was considered to be down-regulated when the number of CD3-ζ+ cells was less than 33% of the number of CD3-ε+ cells (CD3-ζ/ε <0.33, Ð or +). When there was disagreement between the two observers, slides were reviewed together until agreement was reached.
Statistical analysis
Frequencies of CD3-ζ down-regulation were compared between test groups using the FisherÕs exact test. Differences were regarded as significant when P < 0.05.
RESULTS
CD3-ζ expression in primary cervical carcinomas
CD3+ cells, as determined by staining of the ε chain of the CD3 complex, infiltrating the tumour fields were detectable in all 24 primary tumours studied. The ζ chain expression in the infiltrate was considerably reduced compared to CD3-ε expression (defined by a CD3-ζ/ε ratio of less than 0.33) in 17/24 (71%) of the primary cervical carcinomas. Results obtained for all the studied tumours are summarized in Table 1 . Although we only quantified the number of CD3-ζ+ cells within tumour fields, we also observed a reduced ζ chain expression (as compared to CD3-ε) in the stroma surrounding the tumour areas (data not shown). However, this reduction generally appeared to be less severe than the reduction observed in infiltrating cells within the tumour mass. Figures 1C  and D show the respective CD3-ε and CD3-ζ expression in lymphocytes infiltrating a primary cervical tumor. A marked reduction of ζ chain expression is apparent. The numeric differences between CD3-ε+ and CD3-ζ+ cells was not due to immunohistochemical artifacts, since in slides with severely reduced ζ chain expression it was always possible to find at least a few CD3-ζ+ cells serving as internal positive controls. Although the necessary microwave retrieval step on paraffin sections resulted in considerably weaker staining for CD3-ζ than for CD3-ε (Figure 1 ), this did not lead to a bias in the quantitation, as evidenced by results from frozen tissue sections: CD3-ζ staining on frozen sections did not require antigen retrieval and was comparable in intensity to the CD3-ε staining, while similarly reduced CD3-ζ/ε ratios were found for paraffin and frozen sections from the same tumours (n = 5, Table 1 ). CD3-ε and CD3-ζ positive lymphocytes ( Figures 1A and B, respectively) are present in equal numbers in a hyperplastic tonsil biopsy. A mean CD3-ζ/ε ratio of 0.9 was found for the total of five hyperplastic tonsils that were tested with only minor variations between the different tonsil biopsies. These tonsils served as positive controls in all performed tests. We also determined CD3-ζ expression in three premalignant cervical intraepithelial neoplastic (CIN) lesions (CIN III), which are regarded as the direct precursor lesions of cervical carcinoma, and in three cervical biopsies without apparent epithelial abnormalities. We observed considerably reduced CD3-ζ expression in infiltrating lymphocytes in two out of three CIN III lesions (CD3-ζ/ε <0.33) with the remaining CIN III lesion showing a less pronounced reduction of CD3-ζ expression (0.33 < CD3-ζ/ε <0.67). The biopsies with normal cervical epithelium were harder to analyse due to the absence of lymphocytes infiltrating the squamous epithelial layers. However, no difference in the amount of CD3-ε+ and CD3-ζ+ cells was detected in T-cells present in the stroma directly underneath the epithelial basal layer.
CD3-ζ expression in tumour-positive and tumour-negative pelvic lymph nodes
A total of 15 tumour-negative and seven tumour-positive pelvic lymph nodes were examined for CD3-ε and ζ expression. In 11 out of 15 tumour-negative lymph nodes CD3-ε and CD3-ζ were equally expressed, while only in one biopsy a considerably reduced CD3-ζ expression was observed (CD3-ζ/ε < 0.33). In tumour-positive lymph nodes, tumour nests were usually surrounded by a thick band of CD3-ε+ cells, with some T-cells intermingled with the tumour cells. In all seven tumour-positive lymph nodes studied, CD3-ζ expression was strong and comparable to CD3-ε expression (+++ in 6/7 and ++ in 1/7 cases, see Table 1 ). Also on lymphocytes in between metastasizing tumour cells a good CD3-ζ expression was observed. CD3-ε and CD3-ζ expression in a tumour-positive lymph node are shown in Figure  1E and F, respectively.
CD3-ζ expression in tumour-positive and tumour-negative lymph nodes derived from the same patient was mostly comparable, except for case no. 7 where a reduced CD3-ζ expression (comparable to the expression in the primary tumour) was observed in the tumour-negative lymph node, while CD3-ε and CD3-ζ were equally expressed in the tumour-positive lymph node (Table 1) .
From 14 patients both the primary tumour and tumour-negative lymph nodes were available. In addition, tumour-positive lymph nodes were also available from six of these patients (see Table 1 ). The frequency of CD3-ζ loss (CD3-ζ/ε < 0.33) in the primary tumours was significantly higher (11/14, 79%) than in the corresponding tumour-negative lymph nodes (1/14, 7%, P < 0.0005). Similarly, the frequency of CD3-ζ loss was higher in the primary tumours (5/6, 83%) as compared to the corresponding metastasispositive draining lymph nodes (0/6, 0%, P < 0.02). Also, the frequency of CD3-ζ down-regulation in the total of the tested primary carcinomas (17/24, 71%) was significantly higher than the frequency of down-regulation in all the lymph nodes (both tumour-positive and tumour-negative) studied (1/22, 4.5%, P < 0.00001, Figure 2 ).
DISCUSSION
In this study we report a putative local impairment of cellular immune functions in primary cervical carcinoma due to the loss of the signal transducing ζ chain from the TCR/CD3 complex of tumour-infiltrating lymphocytes. In the majority of our carcinoma samples, a down-regulation of CD3-ζ expression was observed as compared to the expression of CD3-ε in the same tumour fields on consecutive slides. In contrast, CD3-ζ expression was retained in T-cells surrounding metastatic deposits in draining pelvic lymph nodes and also in tumour-negative lymph nodes. The difference in expression levels between tumours and draining lymph nodes suggests that the observed loss of CD3-ζ expression is caused by factors released from the primary tumour Figure 2 CD3-ζ expression levels in primary cervical carcinomas (prim. tumours, n = 24) and in both tumour-negative (n = 15) and in tumour-positive (n = 7) draining pelvic lymph nodes (pelvic LN, total: n = 22). CD3-ζ expression is classified according to the ratio of the number of ζ+ cells and the number of CD3-∈+ cells in the same areas in consecutive tissue sections; -: CD3-ζ/∈ = 0, +: 0 < CD3-ζ/∈ < 0.33, + +: 0.33 < CD3-ζ/∈ < 0.66, + + +: 0.66 < CD3-ζ/∈ < 1.0. CD3-ζ expression was considered to be lost in case of -or + classification (CD3-ζ/∈ < 0.33) and may be a localized effect. This is in keeping with previous observations in colon carcinoma where CD3-ζ loss on mucosainfiltrating T-cells was found to be inversely correlated to the distance from the primary tumour site (Matsuda et al, 1995) . However, employing FACS analysis, a down-regulation of CD3-ζ has also been reported on peripheral lymphocytes from cervical carcinoma patients (Kono et al, 1996a) , indicating that this is not merely a local effect. The latter study did not include an analysis of tumour-infiltrating lymphocytes, but our study indicates that these cells would have been likely to have had a more pronounced loss of CD3-ζ expression. NK-cells can also express ζ chains which associate with the low-affinity (type III) Fcγ receptor (CD16) (Kiessling et al, 1996) . Indeed, besides loss of CD3-ζ from T-cells, Kono et al (1996a) also showed down-regulation of ζ chains on NK-cells in the peripheral blood of cervical carcinoma patients. By staining carcinoma sections for the NK-cell marker CD56, we found relatively few NK-cells infiltrating the tumour areas (data not shown). We therefore conclude that the observed change in ζ chain expression in cervical tumours is mainly due to the modulation of CD3-ζ expression on tumour-infiltrating T-cells.
Our observation of putatively impaired T-cell functions in cervical neoplasia by ζ chain down-regulation may seem to conflict with our recently published findings of an increase in granzyme B expression by CD8+ T-cells in cervical carcinoma, which is a clear sign of cytotoxic T-cell (CTL) activation (Bontkes et al, 1997) . However, in early stage colon carcinomas (DukeÕs A) we previously reported a similar increase in granzyme positivity with a simultaneously decreased ζ chain expression (Mulder et al, 1997) . It seems likely that, in tumours, the degree of T-cell activation on the one hand and T-cell suppression on the other, will depend on the local balance between the availability of tumour antigens accompanied by appropriate pro-inflammatory signals and tumour-derived immunosuppressive factors (Matzinger, 1994; Chouaib et al, 1997) . To further study the direct relationship between ζ chain expression and the ability of T-cells to express granzyme B, a double-staining method for these markers will have to be developed.
The mechanisms that are responsible for ζ chain loss in tumourinfiltrating T-cells remain largely unclear. Experiments in tumourbearing mice have shown that the levels of ζ chain mRNA were not affected but that proteolysis of the ζ chain was increased. Lysosomal degradation was implicated as the cause of this increased rate of ζ chain turnover (Correa et al, 1997) . Immunosuppressive cytokines such as IL-10 and TGF-β, possibly tumour-derived, might seem obvious causative agents, but were shown to have no effect on CD3-ζ expression in vitro (Kiessling et al, 1996) . Recently, hydrogen peroxide derived from tumour-associated macrophages was found to down-modulate CD3-ζ expression on peripheral lymphocytes (Kono et al, 1996b) . Interestingly, macrophages isolated from lymph nodes with melanoma metastases were shown to inhibit CD3-ζ expression through contact-dependent mechanisms (Kiessling et al, 1996) . Whether macrophage-derived factors are the main causative agents responsible for the in vivo loss of CD3-ζ expression remains to be established.
There are several possible explanations for the difference in CD3-ζ expression we observed between primary cervical carcinomas and metastasis-positive lymph nodes: a differential expression of tumour-or macrophage-derived factors with ζ chain modulating capacities in primary tumours and metastases, higher levels of IL-2 in lymph nodes which may restore CD3-ζ expression (Kiessling et al, 1996) , or a higher turnover rate of T-cells in lymph nodes as compared to T-cells infiltrating the primary tumour. A murine study demonstrated that T-cells must be exposed for at least 26 days to the putative tumour-released factor, in order for the CD3-ζ chain to be down-regulated (Mizoguchi et al, 1992) . Thus, a rapid turnover of T-cells in the lymph nodes might protect them from ζ chain loss. Kono et al (1996a) reported that the loss of CD3-ζ expression on peripheral lymphocytes was already apparent in patients with premalignant cervical lesions. This is in keeping with our finding of a reduced CD3-ζ expression on epithelium-infiltrating lymphocytes in two out of three tested CIN III lesions. It remains to be established whether decreased CD3-ζ expression is directly correlated to the progression of cervical neoplastic lesions or rather is a consequence of HPV infections per se. It is conceivable that CD3-ζ down-modulation is a reaction to chronic antigenic stimulation resulting from persistent HPV infections. In that case, CD3-ζ loss might affect HPV-specific T-cell tolerance as has been hypothesized for other pathogen-or tumour-specific immune responses (Levey and Srivastava, 1996) . This notion is in keeping with the observed loss of CD3-ζ in such a chronic inflammatory condition as rheumatoid arthritis (Kiessling et al, 1996; Maurice et al, 1998) . Whether only a generalized or also a specific effect, in either case the loss of CD3-ζ from the signal transduction machinery of Tcells is likely to hamper effective cellular immune responses to HPV-transformed keratinocytes in (pre)malignant cervical lesions.
In conclusion, reduced CD3-ζ expression on T-cells infiltrating primary cervical carcinomas may result in an impaired cell-mediated anti-tumour response. In order for vaccination strategies to be successful, it may be essential to first identify and counteract mechanisms leading to this loss of CD3-ζ.
